CAIX PET (89Zr-girentuximab)
CAIX PET is a scan using an antibody against a protein almost unique to clear-cell kidney cancer, to tell cancer from benign kidney lumps without a biopsy.
ZIRCON phase 3 (2023): sensitivity 86%, specificity 87% for clear-cell RCC in indeterminate renal masses. Telix's TLX250-CDx received an FDA complete response letter in 2025 (manufacturing); resubmission planned. Also a theranostic pair with 177Lu-girentuximab (STARLITE trials).
How it works
89Zr-labelled anti-CAIX antibody girentuximab imaged 5 days after injection; CAIX is a HIF target expressed in >95% of clear-cell RCC via VHL loss.
- Non-invasive histology-level specificity
- Whole-body staging of clear-cell disease
- Five-day imaging delay; 89Zr dose
- Not yet approved (CRL 2025)
Latest papers
topQuery for this technology: (TITLE:"CAIX PET" OR ABSTRACT:"CAIX PET" OR TITLE:"89Zr-girentuximab" OR ABSTRACT:"89Zr-girentuximab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAIX PET (89Zr-girentuximab), not a curated reading list.